113 related articles for article (PubMed ID: 9621152)
21. The use of pegylated interferon a-2a in a cohort of Greek patients with mycosis fungoides.
Patsatsi A; Papadavid E; Kyriakou A; Georgiou E; Koletsa T; Avgeros C; Koumourtzis M; Lampadaki K; Tsamaldoupis A; Lazaridou E; Stratigos A; Nikolaou V
J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):e291-e293. PubMed ID: 34753217
[No Abstract] [Full Text] [Related]
22. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome.
Avilés A; Nambo MJ; Neri N; Castañeda C; Cleto S; Gonzalez M; Huerta-Guzmán J
Cancer Biother Radiopharm; 2007 Dec; 22(6):836-40. PubMed ID: 18158775
[TBL] [Abstract][Full Text] [Related]
23. Interferon-α2b-induced STAT3 suppression in myeloid-derived suppressor cells in mycosis fungoides.
Geskin LJ; Akilov OE; Schowalter MK; Falo LD
Cancer Immunol Immunother; 2018 Jul; 67(7):1177-1178. PubMed ID: 29619509
[No Abstract] [Full Text] [Related]
24. [Prognostic factors in Raynaud's phenomenon: usefulness of antinuclear antibodies and of periungual capillaroscopy].
Passiu G; Sebastiani GD; Galeazzi M; Tuveri MA; Nicosia PM; Boirivant R
Medicina (Firenze); 1990; 10(4):405-7. PubMed ID: 2099984
[TBL] [Abstract][Full Text] [Related]
25. Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient with mycosis fungoides.
Braathen LR; Stavem P
BMJ; 1989 Jun; 298(6689):1713. PubMed ID: 2503190
[No Abstract] [Full Text] [Related]
26. Raynaud's phenomenon and digital necrosis induced by interferon-alpha.
Bachmeyer C; Farge D; Gluckman E; Miclea JM; Aractingi S
Br J Dermatol; 1996 Sep; 135(3):481-3. PubMed ID: 8949451
[TBL] [Abstract][Full Text] [Related]
27. Interferon-based treatment for patients with mycosis fungoides and hepatitis C virus infection: a case series.
Kyvernitakis A; Duvic M; Mahale P; Torres HA
Am J Clin Dermatol; 2014 Oct; 15(5):451-6. PubMed ID: 24934807
[TBL] [Abstract][Full Text] [Related]
28. Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.
Simoni R; Cavalieri R; Coppola G; Ricciotti L; De Pità O; Criscuolo D; Covelli A; Papa G; Mandelli F
J Biol Regul Homeost Agents; 1987; 1(2):93-9. PubMed ID: 3504088
[TBL] [Abstract][Full Text] [Related]
29. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
Rychlik-Golema W; Mastej K; Adamiec R
Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
[TBL] [Abstract][Full Text] [Related]
30. Systemic autoimmune disease and Raynaud's phenomenon: a common, immunologically mediated, vascular basis?
Kallenberg CG; Wouda AA; The TH
Neth J Med; 1984; 27(9):322-6. PubMed ID: 6334812
[No Abstract] [Full Text] [Related]
31. Immunologic abnormalities in idiopathic Raynaud's phenomenon.
Moutsopoulos HM; Constantopoulos S; Gerber LH; Lawley TJ
Clin Exp Rheumatol; 1983; 1(1):45-8. PubMed ID: 6681124
[TBL] [Abstract][Full Text] [Related]
32. Peginterferon alfa-2b for mycosis fungoides.
Yanagi T; Shimizu T; Ujiie H; Ito M; Abe R; Tsuji-Abe Y; Hige S; Shimizu H
Arch Dermatol; 2006 May; 142(5):649-51. PubMed ID: 16702510
[No Abstract] [Full Text] [Related]
33. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
Foss FM; Ihde DC; Breneman DL; Phelps RM; Fischmann AB; Schechter GP; Linnoila I; Breneman JC; Cotelingam JD; Ghosh BC
J Clin Oncol; 1992 Dec; 10(12):1907-13. PubMed ID: 1453206
[TBL] [Abstract][Full Text] [Related]
34. Clinical utility of antinuclear antibody tests in children.
McGhee JL; Kickingbird LM; Jarvis JN
BMC Pediatr; 2004 Jul; 4():13. PubMed ID: 15245579
[TBL] [Abstract][Full Text] [Related]
35. Widespread comedones as the sole clinical manifestation of follicular mycosis fungoides.
Torres T; Velho G; Alves R; Selores M
Eur J Dermatol; 2010; 20(4):534-5. PubMed ID: 20413371
[No Abstract] [Full Text] [Related]
36. Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma.
Furudate S; Fujimura T; Kakizaki A; Hidaka T; Asano M; Aiba S
J Dermatol Sci; 2016 Sep; 83(3):182-9. PubMed ID: 27342040
[TBL] [Abstract][Full Text] [Related]
37. Fingertip necrosis in a 6-year-old child with primary Raynaud's phenomenon.
Bhat W; Akhtar S; Knight S
J Hand Surg Eur Vol; 2012 May; 37(4):363-5. PubMed ID: 22190563
[No Abstract] [Full Text] [Related]
38. Serum and tissue CTACK/CCL27 chemokine levels in early mycosis fungoides may be correlated with disease-free survival following treatment with interferon alfa and psoralen plus ultraviolet A therapy.
Goteri G; Rupoli S; Campanati A; Zizzi A; Picardi P; Cardelli M; Giantomassi F; Canafoglia L; Marchegiani F; Mozzicafreddo G; Brandozzi G; Stramazzotti D; Ganzetti G; Lisa R; Simonetti O; Offidani A; Federici I; Filosa G; Leoni P
Br J Dermatol; 2012 May; 166(5):948-52. PubMed ID: 22233400
[TBL] [Abstract][Full Text] [Related]
39. [Raynaud syndrome complicated by digital gangrene during treatment with interferon-alpha].
Liozon E; Delaire L; Lacroix P; Labrousse F; Ly K; Fauchais AL; Loustaud-Ratti V; Vidal J; Liozon F; Vidal E
Rev Med Interne; 1997; 18(4):316-9. PubMed ID: 9161559
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
